NC
MACK

Nexthera Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Nexthera Capital’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,576
Closed -$284K – 55
2015
Q4 		$284K Buy
+4,576
New +$322K 0.4% 33

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Nexthera Capital's MACK Position: Q1 2016 in Review

Nexthera Capital sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2016, closing a stake of 4,576 shares — an estimated $284K sold.

Nexthera Capital first reported a position in MACK in Q4 2015 and held it in 1 quarter. The position peaked at $284K in Q4 2015. 139 funds tracked by Wall St. Rank hold MACK as of Q1 2016.

  • Nexthera Capital reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Nexthera Capital sold 4,576 Merrimack Pharmaceuticals, Inc. shares in Q1 2016, an estimated $284K.
  • Nexthera Capital first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Nexthera Capital's Merrimack Pharmaceuticals, Inc. position peaked at $284K in Q4 2015.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2016.

Based on Nexthera Capital's 13F filing for Q1 2016, filed 13 May 2016.